Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529653 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL3137862 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5538884 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5531361 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5531518 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5537297 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5538451 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5538578 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5533163 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 | |
| SCHEMBL5535737 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCYP17A1GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | claimed |
| JP-2011524416-A | — | — | 2011-09-01 | — | — | JP | claimed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010005480-A9 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | claimed |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-9750698-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9700521-B2 | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9381198-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | disclosed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010005480-A9 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010005480-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | BIOVASCULAR, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20070044831-A1 | Electrolyte composition and dye-sensitized solar cell | NATIONAL UNIVERSITY CORPORATION KYUSHU INSTITUTE OF TECHNOLOGY (JP) | 2007-03-01 | — | — | US | disclosed |
| US-4568676-A | SYNERGISTIC INHIBITION | THOMAS JEFFERSON UNIVERSITY (US) | 1986-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324710-A1 | Controlled release dosage forms for platelet inhibitor such as anagrelide, optionally in combination with other drugs; prevention of vaso-occlusive events, such as embolism | PF4, PLAT, VASP | TBXAS1 82/4885TBXA2R 16/4885CYP17A1 2545/4885 |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | TBXAS1 42/4885TBXA2R 4/4885CYP17A1 2479/4885 |
| US-20160051552-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | TBXAS1 42/4885TBXA2R 4/4885CYP17A1 2479/4885 |
| US-20180153810-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | TBXAS1 42/4885TBXA2R 4/4885CYP17A1 2479/4885 |
| US-20170112767-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | TBXAS1 42/4885TBXA2R 4/4885CYP17A1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.